Head to Head Review: Endologix (ELGX) versus Its Rivals
Endologix (NASDAQ: ELGX) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its competitors? We will compare Endologix to similar businesses based on the strength of its earnings, risk, analyst recommendations, institutional ownership, valuation, profitability and dividends.
This table compares Endologix and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 3.9% of Endologix shares are owned by insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Endologix has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Endologix’s competitors have a beta of 0.21, suggesting that their average stock price is 79% less volatile than the S&P 500.
Earnings and Valuation
This table compares Endologix and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Endologix||$192.93 million||-$154.67 million||-5.65|
|Endologix Competitors||$1.67 billion||$207.58 million||61.28|
Endologix’s competitors have higher revenue and earnings than Endologix. Endologix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current ratings and target prices for Endologix and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Endologix presently has a consensus target price of $5.36, suggesting a potential upside of 2.04%. As a group, “Medical Devices & Implants” companies have a potential upside of 39.83%. Given Endologix’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Endologix has less favorable growth aspects than its competitors.
Endologix competitors beat Endologix on 8 of the 12 factors compared.
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.